We’re delighted to be featured in Sifted’s recent ranking, which lists the 20 most promising early-stage cancer tech startups to watch across Europe.
Sponsored by Debiopharm, who recently launched a new seed Innovation Fund, Sifted scouted hundreds of early-stage oncology startups across Europe. We are thrilled to be selected, and thank Sifted and Debiopharm for the recognition.
Read the Sifted article here.
Find out more about our platform FarrSight® here.